Emerging Treatment Options for Migraine.

Emerging Treatment Options for Migraine. Ann Acad Med Singapore. 2020 Apr;49(4):226-235 Authors: Zhao YJ, Ong JJY, Goadsby PJ Abstract Migraine is one of top 5 medical conditions that contribute to Years Lived with Disability and affects approximately 1 billion people from around the world. To date, preventive treatment and acute therapies for migraine are limited, have undesirable side effects and are poorly tolerated in patients. In the last few decades, considerable advances in our understanding of migraine and its pathophysiology have paved the way for the development of targeted treatment options. Calcitonin gene-related peptide (CGRP) plays an integral role in the neurobiology of migraine, and new classes of drugs that target the CGRP pathway have included gepants and CGRP pathway monoclonal antibodies. Serotonin 5-HT1F receptor agonists-namely ditans-have also been developed to treat acute migraine. Lastly, non-invasive neuromodulation offers another treatment option for migraine patients who prefer treatments that have fewer side effects and are well tolerated. In this review, we discussed emerging treatment options for migraine that were made available in recent years. PMID: 32419007 [PubMed - in process]
Source: Annals of the Academy of Medicine, Singapore - Category: General Medicine Authors: Tags: Ann Acad Med Singapore Source Type: research